INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease
Inmune Bio Emerges as Biotech Innovator in 2023
INmune Bio Holds an Investor and Analyst Webinar
Maxim Group Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $22
Inmune Bio's Promising Pipeline and Financial Stability Justify Buy Rating
INmune Bio | 8-K: INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update
Earnings Call: INmune Bio Q3 2024 Results Show Progress in Clinical Trials
BTIG Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $21
Scotiabank Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $22
INmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript Summary
INmune Bio GAAP EPS of -$0.60 Misses by $0.10
INmune Bio | 10-Q: Q3 2024 Earnings Report
Express News | INmune Bio Q3 Operating Income USD -12.286 Million
Press Release: INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update
INmune Bio 3Q Loss/Shr 60c >INMB
Here Are the Major Earnings After the Close Today
INmune Bio Q3 2024 Earnings Preview
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB
Earnings Preview: INmune Bio to Report Financial Results Post-market on October 31
Highbridge Capital Management's Strategic Acquisition of INmune Bio Inc Shares